Date: 2011-06-07
Type of information: R&D agreement
Compound: monoclonal therapeutic antibodies for the treatment of inflammatory and autoimmune diseases
Company: Antitope (UK) NasVax (Israel)
Therapeutic area: Inflammatory diseases - Autoimmune diseases
Type agreement: R&D
Action mechanism:
Disease:
Details: Antitope has announced a research collaboration with NasVax Ltd. for the generation of monoclonal therapeutic antibodies for the treatment of inflammatory and autoimmune diseases. During the collaboration, Antitope will apply its Composite Human AntibodyTM technology to generate fully-humanized antibodies. The resulting fully-humanized antibodies will be devoid of T cell epitopes and will have a reduced risk of clinical immunogenicity.
Financial terms:
Latest news:
